[Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].

Abstract

BACKGROUND AND OBJECTIVE:

As the first epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in China, icotinib shows promising anticancer activity in vitro and vivo. The phase III clinical study (ICOGEN) showed that icotinib has a good efficacy and tolerability in Chinese patients with advanced non-small cell lung cancer (NSCLC) compared with gefitinib. This retrospective study aims to evaluate the efficacy and tolerability of icotinib monotherapy for advanced NSCLC patients with EGFR mutation and wild-type patients in our hospital.

METHODS:

Patients with advanced NSCLC who were treated with icotinib in Zhejiang Cancer Hospital were retrospectively analyzed from August, 2011 to August, 2012. Survival was estimated using Kaplan-Meier analysis and Log-rank tests.

RESULTS:

The clinical data of 49 patients (13 with wild-type and 36 with EGFR mutation) with NSCLC were enrolled in the current study. The patients' overall objective response rate (ORR) was 58.3% and the disease control rate (DCR) in 36 EGFR mutation patients was 88.9%. The ORR was 7.7% and DCR was 53.8% in the wild-type patients. Median progression-free survival (PFS) with icotinib treatment in EGFR mutation patients was 9.5 months and 2.2 months in wild-type patients (P<0.001). Nineteen patients with EGFR mutation received icotinib as first-line and 17 in further-line treatment. The PFS was 9.5 months in the first-line and 8.5 months for second-line or further-line patients (P=0.41). Median overall survival (OS) in EGFR mutation patients was not reached, but was 12.6 months in wild-type patients. Most of the drug-related adverse events were mild (grade I or II) and reversible with no grade IV toxicity.

CONCLUSIONS:

Icotinib monotherapy showed significant antitumor activity in advanced NSCLC EGFR mutation patients. The toxicity was well tolerated and acceptable.

• Authors: Zhengbo Song, Xinmin Yu, Jufen Cai, Lan Shao, Baochai Lin, Chunxiao He, Beibei Zhang, Yiping Zhang
• Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer (Zhongguo Fei Ai Za Zhi) Vol. 16 Issue 3 Pg. 138-43 (Mar 2013) ISSN: 1999-6187 [Electronic] China
• PMID: 23514942 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Crown Ethers
• Quinazolines
• icotinib
• EGFR protein, human
• ErbB Receptors

Topics

• Antineoplastic Agents (adverse effects, pharmacology, therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy, genetics, pathology)
• Crown Ethers (adverse effects, pharmacology, therapeutic use)
• ErbB Receptors (genetics)
• Female
• Humans
• Lung Neoplasms (drug therapy, genetics, pathology)
• Male
• Middle Aged
• Mutation
• Neoplasm Staging
• Quinazolines (adverse effects, pharmacology, therapeutic use)
• Retrospective Studies
• Safety
• Survival Analysis